CN1688553A - 化学方法 - Google Patents

化学方法 Download PDF

Info

Publication number
CN1688553A
CN1688553A CNA038141698A CN03814169A CN1688553A CN 1688553 A CN1688553 A CN 1688553A CN A038141698 A CNA038141698 A CN A038141698A CN 03814169 A CN03814169 A CN 03814169A CN 1688553 A CN1688553 A CN 1688553A
Authority
CN
China
Prior art keywords
alkyl
formula
compound
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038141698A
Other languages
English (en)
Chinese (zh)
Inventor
A·波罗尔
M·钟
杰弗里·艾伦·斯塔福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1688553A publication Critical patent/CN1688553A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038141698A 2002-06-17 2003-06-17 化学方法 Pending CN1688553A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38934902P 2002-06-17 2002-06-17
US60/389,349 2002-06-17

Publications (1)

Publication Number Publication Date
CN1688553A true CN1688553A (zh) 2005-10-26

Family

ID=29736629

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038141698A Pending CN1688553A (zh) 2002-06-17 2003-06-17 化学方法

Country Status (10)

Country Link
US (1) US20060252943A1 (https=)
EP (1) EP1515955A4 (https=)
JP (1) JP2005529954A (https=)
CN (1) CN1688553A (https=)
AU (1) AU2003276125B2 (https=)
CA (1) CA2489648A1 (https=)
IL (1) IL165286A0 (https=)
MX (1) MXPA04012860A (https=)
PL (1) PL374963A1 (https=)
WO (1) WO2003106416A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060848A (zh) * 2010-12-09 2011-05-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
CN103232443A (zh) * 2013-02-01 2013-08-07 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
CN103373963A (zh) * 2012-04-28 2013-10-30 上海医药工业研究院 盐酸帕唑帕尼的中间体及其制备方法
CN103373989A (zh) * 2012-04-28 2013-10-30 上海医药工业研究院 盐酸帕唑帕尼的中间体的制备方法
CN103450085A (zh) * 2013-08-15 2013-12-18 凯莱英医药集团（天津）股份有限公司 一种盐酸帕唑帕尼关键中间体的制备方法
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
CN116554106A (zh) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US8003744B2 (en) 2003-08-25 2011-08-23 Kaneka Corporation Curing composition with improved heat resistance
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA016227B1 (ru) 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
HRP20110244T1 (hr) 2005-11-29 2011-04-30 Glaxosmithkline Llc Postupak liječenja raka
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008128231A1 (en) 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US20120197019A1 (en) * 2009-10-23 2012-08-02 Dharmesh Surendra Bhanushali Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9150547B2 (en) 2010-11-29 2015-10-06 Hetero Research Foundation Process for the preparation of pazopanib using novel intermediate
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014097152A1 (en) * 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
US9802923B2 (en) 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110028495B (zh) * 2019-05-24 2019-12-03 济南爱思医药科技有限公司 帕唑帕尼盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
JP3711443B2 (ja) * 2000-10-25 2005-11-02 セイコーエプソン株式会社 インクジェット式記録装置
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060848A (zh) * 2010-12-09 2011-05-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
CN102060848B (zh) * 2010-12-09 2013-09-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
CN103373963A (zh) * 2012-04-28 2013-10-30 上海医药工业研究院 盐酸帕唑帕尼的中间体及其制备方法
CN103373989A (zh) * 2012-04-28 2013-10-30 上海医药工业研究院 盐酸帕唑帕尼的中间体的制备方法
CN103373963B (zh) * 2012-04-28 2015-07-08 上海医药工业研究院 盐酸帕唑帕尼的中间体及其制备方法
CN103373989B (zh) * 2012-04-28 2016-04-13 上海医药工业研究院 盐酸帕唑帕尼的中间体的制备方法
CN103232443A (zh) * 2013-02-01 2013-08-07 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
CN103450085A (zh) * 2013-08-15 2013-12-18 凯莱英医药集团（天津）股份有限公司 一种盐酸帕唑帕尼关键中间体的制备方法
CN103450085B (zh) * 2013-08-15 2015-11-18 凯莱英医药集团（天津）股份有限公司 一种盐酸帕唑帕尼关键中间体的制备方法
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
CN116554106A (zh) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法

Also Published As

Publication number Publication date
PL374963A1 (en) 2005-11-14
IL165286A0 (en) 2005-12-18
JP2005529954A (ja) 2005-10-06
MXPA04012860A (es) 2005-09-20
EP1515955A2 (en) 2005-03-23
CA2489648A1 (en) 2003-12-24
AU2003276125B2 (en) 2007-05-17
US20060252943A1 (en) 2006-11-09
EP1515955A4 (en) 2006-05-03
WO2003106416A2 (en) 2003-12-24
WO2003106416A3 (en) 2004-05-06
AU2003276125A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
CN1688553A (zh) 化学方法
CN1549813A (zh) 作为血管生成调节剂的嘧啶胺
CN1305872C (zh) 喹唑啉类化合物的制备方法
CN1174981C (zh) 咪唑并[1,2-a]吡啶和吡唑并[2,3-a]吡啶衍生物
CN1168721C (zh) 5-氰基-2-氨基嘧啶衍生物
CN1227249C (zh) 嘧啶化合物
CN1285580C (zh) 嘧啶化合物
CN1211373C (zh) 用作抗肿瘤药的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶
CN1079097C (zh) 杂二环磺胺衍生物和磺酸酯衍生物
CN1269813C (zh) 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1273466C (zh) 具有唑基的喹啉衍生物和喹唑啉衍生物
CN1252065C (zh) 噌啉化合物
CN1034175C (zh) 吡唑并嘧啶类化合物
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1396833A (zh) 整联蛋白表达抑制剂
CN1882578A (zh) 作为zap－70和/或syk抑制剂的2,4－二(杂)芳基氨基嘧啶衍生物
CN101035769A (zh) 作为激酶抑制剂的嘧啶脲衍生物
CN1406231A (zh) 嘧啶化合物
CN1482912A (zh) 杂芳基脲神经肽yy5受体拮抗剂
CN1446212A (zh) 具有vegf抑制活性的喹啉衍生物
CN1633419A (zh) Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1582281A (zh) Mch受体拮抗剂
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1439009A (zh) 咪唑并嘧啶衍生物和三唑并嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication